HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. It holds a globally diversified portfolio of private and public healthcare companies across biotechnology, medical technology, diagnostics, and therapeutics.
36% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $113.5M (across 103 rounds with reported amounts).
Portfolio
86
Fund Size
—
Top Stage
Series B
Last 12 Mo
9
Team
Thomas Heimann
Head Operations & Investment Solutions
Cindy Chen
Chief Operating Officer HBM Partners Hong Kong Limited
Dr Andreas Wicki
Management, CEO
Dr Elaine V. Jones
Board Member
Dr Rudolf Lanz
Board Member
Dr Stella Xu
Board Member
Hans Peter Hasler
Chairman
Mario G. Giuliani
Board Member
Nina Good
Head Compliance
Matthias Fehr
Head Private Equity
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| CCorxel | Series D | $287M | Sep 2026 |
 Crystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
 Fore Biotherapeutics | Unknown | $67.4M | Jul 2026 |
 Lycia Therapeutics | Series D | $75M | Jun 2026 |
 CellCentric | Series D | $220M | May 2026 |
| CCorxel | Series D | $287M | Jan 2026 |
| CCorxel Pharmaceuticals Limited | Series D | $287M | Jan 2026 |
 Electra | Series C | $183M | Oct 2025 |
| EElectra Therapeutics | Series C | $183M | Oct 2025 |
| TTata 1mg | Unknown | $40M | Sep 2025 |
| Fore Biotherapeutics | Series D | $38M | May 2025 |
| FFore Bio | Series D | $38M | May 2025 |
| AAculys Pharma, Inc. | Series C | — | Mar 2025 |
| CCurevo Vaccine | Series B | $110M | Mar 2025 |
| CCurevo Vaccine (Curevo) | Series B | $110M | Mar 2025 |
| NNumab Therapeutics | Series C | $55M | Jan 2025 |
| AAculys Pharma, Inc. | Series C | — | Jan 2025 |
| CCurevo Vaccine | Series B | $110M | Jan 2025 |
| CCurevo Vaccine (Curevo) | Series B | $110M | Jan 2025 |
| FFore Bio | Series C | $57M | Jan 2025 |
 SphingoTec | Series C | — | Aug 2024 |
 Cartesian | Unknown | $130M | Jul 2024 |
| BBluejay Therapeutics | Series C | $182M | May 2024 |
 Alumis | Series C | $259M | Mar 2024 |
 Shape Memory Medical | Series C | $38M | Mar 2024 |
Top Co-Investors
Last updated: 20 October 2026